Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker RCKT · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | BAG3-DCM Natural History Study NCT07486752 · Dilated Cardiomyopathy (DCM), Cardiovascular Diseases | RCKT Rocket Pharmaceuticals Inc. | — | Not yet recruiting | 30 | Dec 2032 | Registry ↗ |
| Oct 19, 2026 | Danon Disease Natural History Study NCT06214507 · Danon Disease No intervention | RCKT Rocket Pharmaceuticals Inc. | — | Recruiting | 60 | Dec 2029 | Registry ↗ |
| Oct 14, 2026 | PKP2-ACM Natural History Study NCT06644742 · Cardiomyopathies, Heart Diseases | RCKT Rocket Pharmaceuticals Inc. | — | Recruiting | 36 | Dec 2030 | Registry ↗ |
| Oct 6, 2026 | A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease NCT06092034 · Danon Disease RP-A501 | RCKT Rocket Pharmaceuticals Inc. | Phase 2 | Recruiting | 18 | Jun 2028 | Registry ↗ |
| Oct 6, 2026 | Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B NCT03882437 · Danon Disease RP-A501 | RCKT Rocket Pharmaceuticals Inc. | Phase 1 | Completed | 7 | Jul 3, 2025 | Registry ↗ |
| Oct 1, 2026 | A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects… NCT07137338 · Dilated Cardiomyopathy (DCM) RP-A701 is a recombinant viral vector composed of an AAV se… | RCKT Rocket Pharmaceuticals Inc. | Phase 1 | Recruiting | 8 | Jun 2029 | Registry ↗ |
| Apr 16, 2026 | Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency NCT06422351 · Pyruvate Kinase Deficiency RP-L301 | RCKT Rocket Pharmaceuticals Inc. | Phase 2 | Suspended | 10 | Jan 2029 | Registry ↗ |
| Apr 16, 2026 | A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic C… NCT05885412 · PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) RP-A601 | RCKT Rocket Pharmaceuticals Inc. | Phase 1 | Recruiting | 9 | Sep 2028 | Registry ↗ |
| Apr 14, 2026 | Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion… NCT07527975 · Fanconi Anemia RP-L102 | RCKT Rocket Pharmaceuticals Inc. | — | Enrolling by invitation | 14 | May 2038 | Registry ↗ |
| Apr 13, 2026 | Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy NCT04437771 · Fanconi Anemia Complementation Group A, Fanconi Anemia Safety and efficacy assessments | RCKT Rocket Pharmaceuticals Inc. | — | Active, not recruiting | 9 | Jan 17, 2034 | Registry ↗ |
| Dec 22, 2025 | Gene Therapy for Fanconi Anemia, Complementation Group A NCT04248439 · Fanconi Anemia Complementation Group A RP-L102 | RCKT Rocket Pharmaceuticals Inc. | Phase 2 | Active, not recruiting | 5 | May 5, 2026 | Registry ↗ |
| Dec 18, 2025 | Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) NCT06282432 · Leukocyte Adhesion Deficiency | RCKT Rocket Pharmaceuticals Inc. | — | Active, not recruiting | 9 | Oct 4, 2036 | Registry ↗ |
| Sep 5, 2025 | Gene Therapy for Pyruvate Kinase Deficiency (PKD) NCT04105166 · Pyruvate Kinase Deficiency RP-L301 | RCKT Rocket Pharmaceuticals Inc. | Phase 1 | Completed | 4 | Jun 9, 2025 | Registry ↗ |
| May 22, 2024 | Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A NCT04069533 · Fanconi Anemia Complementation Group A RP-L102 | RCKT Rocket Pharmaceuticals Inc. | Phase 2 | Unknown | 7 | Feb 2025 | Registry ↗ |
| Nov 21, 2023 | Natural History of Danon Disease NCT05548855 · Danon Disease Heart Transplant, Cardiac Assistive Device | RCKT Rocket Pharmaceuticals Inc. | — | Completed | 59 | Oct 31, 2023 | Registry ↗ |
| Nov 15, 2023 | A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion… NCT03812263 · Leukocyte Adhesion Defect - Type I RP-L201 | RCKT Rocket Pharmaceuticals Inc. | Phase 1/2 | Completed | 9 | Sep 12, 2023 | Registry ↗ |
| Jul 13, 2022 | A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteop… NCT04525352 · Infantile Malignant Osteopetrosis RP-L401 | RCKT Rocket Pharmaceuticals Inc. | Phase 1 | Terminated | 1 | May 21, 2021 | Registry ↗ |
| Dec 7, 2021 | A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhe… NCT03825783 · Leukocyte Adhesion Defect - Type I RP-L201 | RCKT Rocket Pharmaceuticals Inc. | Phase 1 | Withdrawn | 0 | Oct 2021 | Registry ↗ |
| Nov 24, 2020 | A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtyp… NCT03814408 · Fanconi Anemia Complementation Group A RP-L102 | RCKT Rocket Pharmaceuticals Inc. | Phase 1 | Unknown | 2 | Dec 2020 | Registry ↗ |
19 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:47 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances